Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Rises By 63.7%

Aptose Biosciences Inc. (NASDAQ:APTOGet Free Report) (TSE:APS) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 122,600 shares, an increase of 63.7% from the February 13th total of 74,900 shares. Currently, 6.1% of the company’s stock are short sold. Based on an average daily trading volume, of 395,100 shares, the days-to-cover ratio is presently 0.3 days.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $3.69 on Monday. Aptose Biosciences has a fifty-two week low of $2.39 and a fifty-two week high of $51.61. The stock’s 50-day moving average is $5.13 and its two-hundred day moving average is $8.04. The firm has a market cap of $7.90 million, a P/E ratio of -1.24 and a beta of 1.14.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com started coverage on Aptose Biosciences in a research report on Wednesday, March 5th. They issued a “sell” rating on the stock. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average target price of $130.00.

Check Out Our Latest Stock Report on Aptose Biosciences

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.